Search results for "Cancer Pain"

showing 10 items of 134 documents

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer

2004

Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was to describe pain prevalence among patients diagnosed with advanced non-small-cell lung cancer (NSCLC), impact of pain on quality of life (QoL) and adequacy of pain management. Data of 1021 Italian patients enrolled in three randomised trials of chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13. Analgesic consumption during the 3 weeks following QoL assessment was recorded. Adequacy of pain management was evaluated by the Pain Management Index (PMI). Some pain was reported by 74% of patients (42% mild, 24% …

AdultMalecancer painCancer Researchmedicine.medical_specialtyLung NeoplasmsAnalgesicPainBone NeoplasmsSeverity of Illness Indexlaw.inventionClinicalPain Management IndexRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungInternal medicineEpidemiologySeverity of illnessPrevalencemedicineHumansPain ManagementAgedPain MeasurementRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGuidelineanalgesicMiddle AgedClinical triallung cancerItalyOncologyanalgesicsQuality of LifePhysical therapyFemalebusinessCancer painBritish Journal of Cancer
researchProduct

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

2004

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The…

AdultMalecancer painMaximum Tolerated DosePain medicineAnalgesicPainRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleStatistics Nonparametriclaw.inventionPharmacotherapyRandomized controlled triallawNeoplasmsMedicineHumansTerminally IllProspective StudiesKarnofsky Performance StatusAdverse effectAgedPain MeasurementProbabilityTerminal CareDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedClinical trialAnalgesics OpioidFentanylTreatment OutcomeOncologyOpioidopioid responseAnesthesiaopioid treatmentDrug Therapy CombinationFemaleCancer painbusinessmedicine.drug
researchProduct

A Prospective Randomized Study of Corticosteroids as Adjuvant Drugs to Opioids in Advanced Cancer Patients

2007

This randomized controlled study evaluated the role of corticosteroids as adjuvants to opioid therapy in 76 advanced cancer patients with pain who requiring strong opioids. Patients were divided in 2 groups. Group O received conventional opioid treatment. Group OS received dexamethasone (8 mg orally) along with conventional treatment. Pain and symptom intensity, sense of well-being, and opioid escalation index and distress score were recorded at weekly intervals until death. No differences in pain intensity, opioid consumption, and opioid escalation index were found in 66 patients who survived 33 to 37 days. Corticosteroids did not provide significant additional analgesia to opioids, but p…

AdultMalecorticosteroidmedicine.medical_treatmentAnti-Inflammatory Agentslaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trial030502 gerontologylawNeoplasmsmedicineHumansProspective Studiesopioids in advanced cancer patientsprospective randomized studyProspective cohort studyDexamethasoneAgedPain MeasurementAged 80 and overAnalysis of VarianceChemotherapyadjuvant drugDose-Response Relationship Drugbusiness.industryPalliative CareGeneral MedicineMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidChemotherapy Adjuvant030220 oncology & carcinogenesisAnesthesiaDrug Therapy CombinationFemale0305 other medical scienceCancer painbusinessAdjuvantFollow-Up Studiesmedicine.drugAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Prevalence of Burnout Among Pain Medicine Physicians and Its Potential Effect upon Clinical Outcomes in Patients with Oncologic Pain or Chronic Pain …

2018

Objective To evaluate the prevalence of burnout among physicians treating patients with chronic pain and to assess the potential relationships between the presence of burnout and patients' clinical outcomes such as pain relief, satisfaction with pain control, and quality of life. Design An observational, prospective, and noncomparative study. Setting Pain medicine clinics. Subjects Physicians from medical departments involved in the management of chronic pain. Patients aged ≥18 years who exhibited moderate chronic pain lasting at least three months. Methods Physicians were evaluated with the Maslach Burnout Inventory-Human Services Survey (MBI-HSS). Patients were evaluated with the Charlson…

AdultMalemedicine.medical_specialtyAdolescentPain medicineBurnout PsychologicalBurnout03 medical and health sciences0302 clinical medicineQuality of lifePhysiciansSurveys and QuestionnairesPrevalencemedicineHumansProspective Studies030212 general & internal medicineProspective cohort studyBurnout ProfessionalAgedbusiness.industryChronic painCancer PainGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalAnesthesiology and Pain MedicinePhysical therapyFemaleObservational studyNeurology (clinical)Chronic Painbusiness030217 neurology & neurosurgeryPain Medicine
researchProduct

Personalized Pain Goals and Responses in Advanced Cancer Patients

2020

Abstract Objective To assess the personalized pain intensity goal (PPIG), the achievement of a personalized pain goal response (PPGR), and patients' global impression (PGI) in advanced cancer patients after a comprehensive pain and symptom management. Design Prospective, longitudinal Setting Acute pain relief and palliative/supportive care. Subjects 689 advanced cancer patients. Methods Measurement of Edmonton Symptom Assessment Score (ESAS) and personalized pain intensity goal (PPIG) at admission (T0). After a week (T7) personalized pain goal response (PPGR) and patients' global impression (PGI) were evaluated. Results The mean PPIG was 1.33 (SD 1.59). A mean decrease in pain intensity of …

AdultMalemedicine.medical_specialtyPalliative careAdolescentSymptom assessmentYoung Adult03 medical and health sciences0302 clinical medicineHumansPain ManagementMedicine030212 general & internal medicinePrecision MedicineAcute painAgedPain MeasurementAged 80 and overbusiness.industrySymptom managementMinimal clinically important differenceClinical ResponseGeneral MedicineCancer PainMiddle AgedAdvanced cancerIntensity (physics)Anesthesiology and Pain Medicine030220 oncology & carcinogenesisPhysical therapyFemalePain IntensityNeurology (clinical)businessCancer painGoals
researchProduct

Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms.

1999

The role of nonsteroidal anti-inflammatory drugs (NSAIDs) is well established in the treatment of cancer pain. This class of drugs is considered particularly effective in pain due to somatic mechanisms, although proof of this observation is lacking. To ascertain whether NSAIDs are more effective in specific nociceptive forms of cancer pain, they were administered alone or added to opioids in 32 patients with a sole pain mechanism, somatic pain due to bone metastases (17 patients) or visceral pain (15 patients), respectively. Pain intensity, mean doses of opioids used, and symptoms were recorded after starting NSAID. A significant reduction in pain intensity was found at 3, 7, and 14 days. N…

AdultMalemedicine.medical_specialtyPalliative careEpidemiologyAnalgesicPainOpioidAdverse effectPain ladderDiclofenacInternal medicineNeoplasmsMedicineHumansProspective StudiesCancer painAdverse effectNursing (all)2901 Nursing (miscellaneous)General NursingAgedAnalgesicsbusiness.industryAnti-Inflammatory Agents Non-SteroidalPalliative CareVisceral painMiddle AgedNSAIDVisceraAnesthesiology and Pain MedicineNeurologyOpioidAnesthesiaFemaleMechanismNeurology (clinical)medicine.symptombusinessCancer painmedicine.drugJournal of pain and symptom management
researchProduct

Prevalence of opioid-related dysuria in patients with advanced cancer having pain.

2010

The aim of this study was to assess the prevalence of opioid-induced dysuria in patients with advanced cancer having pain and to evaluate the possible factors associated. A consecutive sample of cancer patients admitted to an acute pain relief and palliative care unit during 8 months was surveyed. Most patients (147, 86.5%) were receiving opioids at admission. The mean age was 65.1 (SD 12.2) and 106 patients were males. Twenty-five patients presented with dysuria at admission (of which 22 were taking opioids, 14.9%). Eleven patients were inserted a bladder catheter at admission for urine monitoring and 18 patients had urinary incontinence. During admission, 31 patients presented dysuria (19…

AdultMalemedicine.medical_specialtyPalliative carePopulationPainUrinary incontinenceurologic and male genital diseasesSettore MED/42 - Igiene Generale E ApplicataDysuriaNeoplasmsInternal medicinePrevalenceHumansMedicineDysuriapatients with advanced cancer painPrevalence of opioid-related dysuriaSex DistributioneducationAgedPain Measurementeducation.field_of_studybusiness.industryPalliative CareCancerGeneral MedicineMiddle AgedOpioid-Related Disordersmedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryAnalgesics OpioidOpioidConcomitantFemaletrial clinicomedicine.symptombusinessCancer painPrevalence of opioid-related dysuria; patients with advanced cancer pain; trial clinicomedicine.drug
researchProduct

Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit

2013

Abstract BACKGROUND: This survey was performed to draw information on pain prevalence, intensity, and management from a sample of patients who were admitted to an oncologic center where a palliative care unit (PCU) has been established for 13 years. METHODS: Cross-sectional survey in an oncological department performed 1 day per month for six consecutive months. RESULTS: Of the 385 patients, 69.1, 19.2, 8.6, and 3.1 % had no pain, mild, moderate, and severe pain, respectively. Inpatients and patients with a low Karnofsky score showed higher levels of pain intensity (p < 0.0005). One hundred twenty-eight patients with pain or receiving analgesics were analyzed for pain management index (PMI)…

AdultMalemedicine.medical_specialtyPalliative careSettore MED/06 - Oncologia MedicaCross-sectional studyPain medicineMEDLINEPainSettore MED/41 - AnestesiologiaOpioidSettore MED/42 - Igiene Generale E ApplicataYoung AdultNeoplasmsPrevalencemedicineHumansPain ManagementChemotherapyKarnofsky Performance StatusYoung adultAgedPain MeasurementAnalgesicsbusiness.industryNursing researchBreakthrough PainPalliative CareMiddle AgedCross-Sectional StudiesOncologyOpioidChemotherapy; Opioid; PainEmergency medicinePhysical therapyFemaleCancer painbusinessmedicine.drugSupportive Care in Cancer
researchProduct

Assessing age and gender in studies of breakthrough pain medications

2014

AbstractObjective:The present review was performed to identify possible differences observed between adults and elderly patients and between males and females in randomized clinical trials of breakthrough pain (BTP).Methods:A systematic search of the existing literature from 1998 to September 2013 was performed. Randomized clinical trials reporting data on older patients were selected.Results:Sixteen comparative studies were selected. The age range of inclusion criteria patients was mainly between 18–80 or ≥18 years. In some cases this data was unreported. The mean age of patients was 48–64 years, but information regarding the number of elderly patients was present in three studies only. Ge…

AdultMalemedicine.medical_specialtyPediatricsBreakthrough PainSubgroup analysislaw.inventionAge and genderSex FactorsRandomized controlled trialOlder patientslawNeoplasmsmedicineHumansPsychiatryAdverse effectAgedRandomized Controlled Trials as Topicbusiness.industryBreakthrough PainAge FactorsGender distributionGeneral Medicinebreakthrough pain cancer painAnalgesics OpioidTreatment OutcomeFemaleCancer painbusinessCurrent Medical Research and Opinion
researchProduct